Alnylam Pharmaceuticals Inc
No standout activity across the feeds we track.
What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran…
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2026-08-11 | Cory A. Booker · D-NJ | Senate | Sold | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve · R-IN | House | Sold | $15,001 - $50,000 |
| 2024-01-29 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2024-01-11 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2023-12-11 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2023-03-06 | Daniel S. Goldman · D-NY | House | Bought | $15,001 - $50,000 |
| 2022-09-28 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
| 2020-11-13 | Josh Gottheimer · D-NJ | House | Sold | $1,001 - $15,000 |
| 2020-04-06 | Josh Gottheimer · D-NJ | House | Bought | $1,001 - $15,000 |
Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.